Scarica l'app Stockscreener
11.21
0.45%
0.05
Dopo l'orario di chiusura:
11.08
-0.13
-1.16%
Precedente Chiudi:
$11.16
Aprire:
$11
Volume 24 ore:
3.56M
Relative Volume:
0.76
Capitalizzazione di mercato:
$1.57B
Reddito:
$67.67M
Utile/perdita netta:
$-412.69M
Rapporto P/E:
-2.9295
EPS:
-3.8266
Flusso di cassa netto:
$-395.87M
1 W Prestazione:
-1.84%
1M Prestazione:
-9.08%
6M Prestazione:
-29.36%
1 anno Prestazione:
-56.70%
Intervallo 1D:
$10.58
$11.24
Intervallo di 1 settimana:
$10.58
$11.99
Portata 52W:
$7.95
$26.35
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Nome
Intellia Therapeutics Inc
Settore
Industria
Telefono
857-285-6200
Indirizzo
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, MRNA, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
11.21 | 1.57B | 67.67M | -412.69M | -395.87M | -3.8266 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-06 | Iniziato | Barclays | Underweight |
| 2026-07-16 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2026-03-02 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-11-12 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-11-11 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-11-07 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-10-28 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2025-02-28 | Downgrade | Goldman | Neutral → Sell |
| 2025-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-04-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-03-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-09-01 | Iniziato | Citigroup | Sell |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-06-16 | Iniziato | BofA Securities | Buy |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-02-18 | Iniziato | William Blair | Outperform |
| 2022-02-07 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Iniziato | Cowen | Outperform |
| 2022-01-07 | Iniziato | Piper Sandler | Overweight |
| 2021-10-05 | Iniziato | Guggenheim | Buy |
| 2021-09-24 | Iniziato | Stifel | Buy |
| 2021-06-28 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-07 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Iniziato | Truist | Buy |
| 2020-10-14 | Iniziato | Wells Fargo | Overweight |
| 2020-09-18 | Iniziato | Goldman | Buy |
| 2020-02-28 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-11-01 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-10 | Iniziato | ROTH Capital | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-11-02 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-10-29 | Iniziato | Credit Suisse | Neutral |
| 2018-09-21 | Iniziato | Raymond James | Mkt Perform |
| 2018-05-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2017-11-01 | Reiterato | Jefferies | Buy |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2017-03-28 | Iniziato | Chardan Capital Markets | Buy |
| 2016-08-05 | Aggiornamento | Jefferies | Hold → Buy |
Mostra tutto
Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie
Intellia Therapeutics, Inc. (NTLA) stock price, news, quote and history - Yahoo Finance UK
The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics - Yahoo Finance
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now - Zacks Investment Research
Intellia Therapeutics (NTLA) Stock Looks Overvalued As Launch Preparations Advance - Yahoo Finance
Intellia Therapeutics, Inc. (NTLA) options chain - Yahoo Finance Australia
Ex-Genentech scientist joins Ira Mellman at Medici; Intellia poaches CMO from Scholar Rock - Endpoints News
Intellia Therapeutics names Jing Marantz as EVP and CMO - The Pharma Letter
Intellia Therapeutics names Jing Marantz as chief medical officer - Investing.com
Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer - Intellia Therapeutics
Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire
Price to earnings forward of Intellia Therapeutics, Inc. – BX:38I - TradingView
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock? - Zacks Investment Research
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock? - Yahoo Finance
To cover taxes, an Intellia Therapeutics (NTLA) officer sells 1,864 shares in a mandatory sale. - Stock Titan
Barclays Initiates Intellia Therapeutics at Underweight With $8 Price Target - marketscreener.com
Barclays Initiates Intellia Therapeutics at Underweight With $8 Price Target - Yahoo Finance
Officer Eliana Clark proposes selling 57,750 Intellia Therapeutics (Nasdaq: NTLA) shares. - Stock Titan
Intellia Therapeutics Q2 2026 Earnings Call Transcript - Benzinga
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Eight new employees got Intellia stock awards, with vesting scheduled over three years. - Stock Titan
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Intellia Therapeutics
Intellia Therapeutics (NTLA), What Is Drawing Fresh Attention Now? - Simply Wall Street
Tangible book value per share of Intellia Therapeutics, Inc. – HAN:38I - TradingView
Intellia Therapeutics, Inc. (NTLA) Stock Forecasts - Yahoo Finance
No-Moat Intellia Therapeutics Provides Pure-Play, Long-Term Exposure to Gene Editing Therapies - Morningstar
Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity - Barchart.com
Intellia Therapeutics Bears Growl Again, This Time About Claude AI -- Yawn! (NASDAQ:NTLA) - Seeking Alpha
Intellia Therapeutics Stock Short Interest Rises to 41.97% - Quiver Quantitative
Gene editing stocks fall after Anthropic’s CRISPR-like discovery - Seeking Alpha
Why Is NTLA Stock Jumping 5% Premarket Today? - Stocktwits
Intellia Therapeutics (NTLA) Stock Gets FDA Priority Review For Lonvo Z Gene Editing Therapy - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances - Yahoo Finance
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry? - Yahoo Finance
How (NTLA) Movements Inform Risk Allocation Models - Stock Traders Daily
Cathie Wood’s ARK sells Twist Bioscience stock, buys more Intellia - investing.com
Cathie Wood’s ARK sells Twist Bioscience stock, buys more Intellia By Investing.com - Investing.com Australia
Tracking Cathie Wood: Adding to Gene Editing Leader Intellia, Trimming Brera Holdings - moomoo.com
Cathie Wood’s ARK adds Intellia stock, trims Brera Holdings - Investing.com
Intellia Therapeutics (NTLA) Secured a Facility for Up to $400M. Is It Worth the Cost? - Yahoo Finance
H.C. Wainwright reiterates Intellia stock rating on FDA review progress By Investing.com - Investing.com Nigeria
Intellia’s Lonvo-z Gains FDA Priority Review for HAE - theglobeandmail.com
Intellia Therapeutics Price Target Maintained With a $25.00/Share by HC Wainwright & Co. - moomoo.com
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug - Yahoo Finance
NTLA Reiterates by Citizens -- Price Target Maintained at $30 - GuruFocus
FDA to Decide on First In Vivo Gene Editor Next Year - GenomeWeb
Intellia Therapeutics Stock Short Interest Rises to 40.35% - Quiver Quantitative
H.C. Wainwright reiterates Intellia stock rating on FDA review progress By Investing.com - Investing.com Canada
NTLA Maintained by Wedbush -- Price Target Raised to $13.00 - GuruFocus
Intellia Therapeutics Inc Azioni (NTLA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Intellia Therapeutics Inc Azioni (NTLA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ELIANA CLARK | Officer |
Oct 05 '26 |
Proposed Sale |
12.75 |
57,750 |
736,312 |
0 |
| LEONARD JOHN M | President and CEO |
Aug 21 '26 |
Sale |
13.00 |
2,785 |
36,205 |
1,147,064 |
| LEONARD JOHN M | Officer |
Aug 20 '26 |
Proposed Sale |
12.95 |
22,675 |
293,641 |
0 |
| LEONARD JOHN M | President and CEO |
Aug 20 '26 |
Sale |
12.60 |
19,890 |
250,614 |
1,149,849 |
| Dulac Edward J III | EVP, Chief Financial Officer |
Jul 22 '26 |
Sale |
11.25 |
8,111 |
91,249 |
148,175 |
| Dulac Edward J III | EVP, Chief Financial Officer |
Jul 02 '26 |
Sale |
18.00 |
4,677 |
84,186 |
156,286 |
| EDWARD DULAC | Officer |
Jul 02 '26 |
Proposed Sale |
17.24 |
4,677 |
80,631 |
0 |
| Dube Michael P | VP, Chief Accounting Officer |
Jul 01 '26 |
Sale |
16.78 |
2,641 |
44,316 |
66,886 |
| BASTA JAMES | EVP, General Counsel |
Mar 02 '26 |
Sale |
13.78 |
1,211 |
16,688 |
156,794 |
| Clark Eliana | EVP, Chief Technical Officer |
Mar 02 '26 |
Sale |
13.78 |
607 |
8,364 |
93,864 |
2.11%
2.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):